Raymond James upgraded Nkarta to Strong Buy from Outperform with an unchanged price target of $13 after the company hosted a webcast to discuss numerous pipeline updates and cash resource reprioritization. Focuses of the call included FDA clearance of he IND for NKX019 in lupus nephritis and the durability data from r/r AML patients seen at last update treated with NKX101 after flu/ara-C LD to be presented by year-end 2023, the analyst said. The firm cites the pivot to autoimmune and the AML outlook for its raised rating.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NKTX:
- Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis
- Nkarta opens new cohort in Phase 1 study of NKX019
- Nkarta announces cost containment measures to extend cash runway
- Nkarta receives FDA clearance of IND application for NKX019
- Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures